Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tidal Therapeutics

Payer focus in the personalised world of oncology and orphan diseases

Personalised medicine is transforming disease understanding and many traditional diagnoses may be fundamentally revised based on the new scientific understanding

- PMLiVE

Sanofi partners with PatientsLikeMe to promote its clinical trials

Online patient community will match patients to the pharma company's trials

Bayer symbol

FDA clears Bayer/ Algeta’s prostate cancer radiotherapy

Approval for Xofigo comes three months ahead of schedule

Sanofi reception

Sanofi fined for slamming Plavix generics

Faces €40.6m penalty for telling doctors generic copies were not suitable substitutes for blockbuster antiplatelet drug

- PMLiVE

FDA expands use of Roche/ Astellas’ Tarceva in lung cancer patients

New indication approved alongside companion diagnostic to detect gene mutation

- PMLiVE

Endocyte appoints Parexel’s Scot Harper to oversee clinical trials

He also previously served at Novartis and Lilly

- PMLiVE

Roche survey says Scottish cancer patients moving house to get treatment

But NHS Scotland hits back at report's "extremely dubious" findings

- PMLiVE

Sanofi appoints Pascale Witz and Peter Guenter

They will lead the pharma company's two new commercial organisations

- PMLiVE

FDA committee turns down Aveo/Astellas’ cancer drug

Tivozanib unable to prove superiority to Bayer's Nexavar

- PMLiVE

FDA says Janssen’s myeloma drug is a ‘breakthrough therapy’

Should speed up regulatory process for daratumumab

Sanofi reception

Sanofi predicts return to growth in second half

But first quarter net income drops by a third

- PMLiVE

Sanofi launches diabetes drug Lyxumia in the UK

Says drug could make multimillion pound savings for the NHS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links